Ευρωπαϊκή Ένωση - Λιθουανικά - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Ευρωπαϊκή Ένωση - Λιθουανικά - EMA (European Medicines Agency)

rotterdam biologics b.v. - bevacizumabas - drėgnas makulos degeneravimas - oftalmologai - treatment of neovascular (wet) age-related macular degeneration (amd).

Ευρωπαϊκή Ένωση - Λιθουανικά - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - kapecitabinas - stomach neoplasms; breast neoplasms; colonic neoplasms; colorectal neoplasms - kapecitabinas - kapecitabinas skiriamas adjuvantiniam pacientų gydymui po iii stadijos (dukeso stadijos c) operacijos su gaubtinės žarnos vėžiu. capecitabine fluorouracilu ir folino metastazavusiu kolorektaliniu vėžiu. capecitabine yra nurodyta pirmos eilės gydymas papildomi skrandžio vėžys, derinant su platinos pagrindu režimas. capecitabine kartu su docetaxel skiriamas pacientams, sergantiems lokaliai išplitusio arba metastazavusio krūties vėžio, kai sugenda citotoksinės chemoterapijos. ankstesnėje terapijoje reikėjo įtraukti antracikliną. capecitabine taip pat nurodė, kaip monotherapy gydomi pacientai su lokaliai išplitusio arba metastazavusio krūties vėžio, kai sugenda taxanes ir pasirinkusios gydymą antraciklinų-kurių sudėtyje chemoterapijos kursu ar kam dar pasirinkusios gydymą antraciklinų terapijos nenurodytas.

Λιθουανία - Λιθουανικά - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - irinotekano hidrochloridas trihidratas - koncentratas infuziniam tirpalui - 20 mg/ml - irinotecan

Λιθουανία - Λιθουανικά - SMCA (Valstybinė vaistų kontrolės tarnyba)

actavis group ptc ehf. - irinotekano hidrochloridas trihidratas - koncentratas infuziniam tirpalui - 20 mg/ml - irinotecan

Λιθουανία - Λιθουανικά - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi polska sp.z.o.o. - irinotekano hidrochloridas trihidratas - koncentratas infuziniam tirpalui - 20 mg/ml - irinotecan

Λιθουανία - Λιθουανικά - SMCA (Valstybinė vaistų kontrolės tarnyba)

actavis group ptc ehf - kapecitabinas - plėvele dengtos tabletės - 150 mg; 500 mg - capecitabine

Λιθουανία - Λιθουανικά - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi oncology plc - kapecitabinas - plėvele dengtos tabletės - 500 mg; 150 mg - capecitabine

Λιθουανία - Λιθουανικά - SMCA (Valstybinė vaistų kontrolės tarnyba)

norameda, uab - kapecitabinas - plėvele dengtos tabletės - 150 mg; 500 mg - capecitabine

Ευρωπαϊκή Ένωση - Λιθουανικά - EMA (European Medicines Agency)

amgen europe b.v. - panitumumabas - kolorektaliniai navikai - antinavikiniai vaistai - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. antruoju-line kartu su folfiri pacientams, kurie gavo pirma-line fluoropyrimidine pagrindu chemoterapija (išskyrus irinotecan). kaip monotherapy po nesėkmės fluoropyrimidine-, oksaliplatinos-ir irinotecan-kurių sudėtyje chemoterapijos režimo.